David Donabedian

David Donabedian has a strong background in venture capital and start-up management. David is currently the Co-founder and CEO of Solu Therapeutics, a precision-medicine focused company developing therapeutics for eliminating disease-driving cells. Prior to this, David served as a Director on the Board of Directors for Anuncia Inc and as a Founding Board Member of Alcyone Therapeutics Inc. David also worked as an Executive Partner/Interim NewCo CEO at Longwood Fund, where they were responsible for sourcing and leading New Co financing and operations. David has experience as a Co-founder, CEO, and Senior Advisor at DEM Biopharma, Inc., a start-up focused on identifying unexplored signals in cancer immunotherapy. David was also a Senior Advisor and later the CEO of ImmuneID, a precision immunology company that raised significant financing. David has held various roles at Longwood Fund, including Venture/Operating Partner and CEO of portfolio companies ImmuneID and Axial Therapeutics. Additionally, David has experience as an Adjunct Lecturer at Brown University and has held senior positions at AbbVie, leading their venture arm and managing a substantial portfolio of venture-backed companies.

David Donabedian attended Saint Anselm College from 1984 to 1988, where they earned their AB degree in Chemistry. David then went on to study at the University of Massachusetts Lowell from 1988 to 1993, completing their PhD in Polymer Chemistry. Later, from 1998 to 2000, David pursued their MBA in General Management at the UNC Kenan-Flagler Business School.